Bioventus Inc. (NYSE:BVS – Get Free Report) SVP Anthony D’adamio sold 3,054 shares of the stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $4.75, for a total value of $14,506.50. Following the completion of the transaction, the senior vice president now directly owns 58,242 shares in the company, valued at approximately $276,649.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Anthony D’adamio also recently made the following trade(s):
- On Friday, March 15th, Anthony D’adamio sold 3,125 shares of Bioventus stock. The shares were sold at an average price of $5.46, for a total value of $17,062.50.
Bioventus Stock Performance
Shares of BVS opened at $4.63 on Tuesday. The company has a quick ratio of 1.01, a current ratio of 1.53 and a debt-to-equity ratio of 1.66. The business has a 50-day simple moving average of $4.96 and a two-hundred day simple moving average of $4.47. The stock has a market cap of $366.56 million, a price-to-earnings ratio of -1.84 and a beta of 0.50. Bioventus Inc. has a 52 week low of $0.86 and a 52 week high of $6.08.
Institutional Trading of Bioventus
A number of hedge funds and other institutional investors have recently bought and sold shares of BVS. LPL Financial LLC purchased a new stake in Bioventus in the fourth quarter worth about $26,000. PNC Financial Services Group Inc. grew its position in shares of Bioventus by 1,845.5% during the first quarter. PNC Financial Services Group Inc. now owns 2,140 shares of the company’s stock worth $30,000 after purchasing an additional 2,030 shares in the last quarter. UBS Group AG grew its position in shares of Bioventus by 72.9% during the fourth quarter. UBS Group AG now owns 12,744 shares of the company’s stock worth $33,000 after purchasing an additional 5,372 shares in the last quarter. Delphia USA Inc. purchased a new stake in shares of Bioventus during the fourth quarter worth about $33,000. Finally, XTX Topco Ltd purchased a new stake in shares of Bioventus during the second quarter worth about $35,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.
Analysts Set New Price Targets
Separately, Craig Hallum increased their target price on Bioventus from $6.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, March 13th.
Read Our Latest Research Report on Bioventus
Bioventus Company Profile
Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
Recommended Stories
- Five stocks we like better than Bioventus
- Low PE Growth Stocks: Unlocking Investment Opportunities
- The Charles Schwab Company Can Hit New Highs
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- How to Invest in Biotech Stocks
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.